Dublin, March 07, 2017 -- Research and Markets has announced the addition of the "The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 10th Edition" report to their offering.
The Worldwide Market for In Vitro Diagnostic Tests, represents the 10th edition of this comprehensive look at the IVD industry. At 1,600 pages report provides market size estimates and projections for the entirety of the clinical diagnostics testing market. It also profiles hundreds of competitors, notes significant acquisitions and other deals, discusses trends and breaks out regional and country markets.
The report provides market size and forecasts to 2021 for defined segments of the IVD market and various sub-segments, including:
- Molecular Assays (Infectious Disease, Blood Screening, Inherited Diseases, Oncology, Pharmacodiagnostics, Tissue Typing, Prenatal)
- Clinical Chemistry (General Chemistries, Workstations, Analyzers Blood Gases, Urinalysis, Critical Care)
- Point-of-Care (POC), (Professional and Self-Testing, Glucose Testing, Pregnancy Tests, drugs of abuse, HIV, H. pylori, Other, OTC/Self Total, Professional POC, Cardiac Markers, Drugs of Abuse, HbA1c, Pregnancy, Other)
- Microbiology and Virology by Test Type (Immunoassays, ID/AST, Infectious Diseases - DNA; ID/AST: Panels and Reagents, automated; Panels and Reagents, manual; Blood Culture; Chromogenic Media; Rapid Micro; Supplies)
- Blood Banking (Grouping, Immunoassay Screens, NAT Screens)
- Tissue-Based Testing - Histology and Cytology (Pap, ISH, IHC, HPV)
- Microbiology Immunoassay Testing (Hepatitis, HIV, STDs, TORCH, Respiratory, Sepsis, Parasitology, Mycology, Others)
- Hematology
- Molecular Tests in Infectious Diseases (HAI, HIV, Hepatitis, GC/Chlamydia, Respiratory, Organism ID, Mycobacteria, TB, Others
- Non-Infectious Disease Immunoassay Sales by Analyte Type (Cardiac markers, Tumor markers, Diabetes/HbA1c, Autoimmune, Allergy, Thyroid, Proteins, Anemia, Fertility, Therapeutic drugs, Tox/Drugs of abuse, Vitamin D)
- Coagulation Tests (Lab-Based, POC, Genetic Markers)
No other report provides similar understanding of the world diagnostics market. For each of the listed segments, 2016 market size, 2021 projection and compound annual growth rate is provided, as well as significant companies in the market and product innovations. The market data is put into a context with real-world industry and medical practice trends.
For more information about this report visit http://www.researchandmarkets.com/research/mf27ss/the_worldwide
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Healthcare Services, Oncology Drugs , In Vitro Diagnostics, Point-of-Care Diagnostics


OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries”
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO
How Technology Is Reshaping Modern Business: From Operations to Customer Experience
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 



